Business
ImmunityBio Expands Vaccine Program to Accelerate Use of “Mix-and-Match” Technologies in Developing and Manufacturing Next-Generation COVID-19 Vaccines
Second-generation vaccines that combine different advanced DNA, RNA, Protein, and Adjuvant components are critical to providing accessible, broad, and
About this update from Immunitybio, Inc.
[{"type":"text","content":"\n\nSecond-generation vaccines that combine different advanced DNA, RNA, Protein, and Adjuvant components are critical to providing accessible, broad, and durable protection against current and future likely SARS-CoV-2 variants\n\n\nBy adding self-amplifying self-adjuvating RNA (SASA-RNA), next-generation nano-lipid carriers, recombinant protein, and adjuvant vaccine technologies to ImmunityBio’s current adenovirus vector vaccine, the company offers one of the most comprehensive vaccine technology platforms\n\n\nSuch combination approaches are already being studied in trials in South Africa, including the fully enrolled Phase 2 SISONKE Boost trial, which is studying ImmunityBio’s hAd 5 as a boost to the Janssen COVID-19 prime\n\n\nThis vaccine consortium is designed to create a comprehensive technology platform to serve as a foundation for the large-scale manufacture of multiple vaccine vectors for pandemic preparedness and for the treatment of cancer\n\n\n CULVER CITY, Calif.--(BUSINESS WIRE)--\nImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced the expansion of the company’s cancer and infectious disease vaccine programs to include self-amplifying self-adjuvating RNA (SASA-RNA), recombinant protein vaccine candidates, and potent adjuvant formulations that enhance the quality, durability and breadth of immune responses to infectious diseases and cancer. When combined with the company’s hAd5 T-cell-based vaccine candidate, the company believes this “mix-and-match” approach will enable a new generation of COVID-19 vaccines that could potentially confer long-term immune memory to overcome the threat of current and future variants of the SARS-CoV-2 virus.\n\nImmunityBio has established partnerships with Amyris, Inc., Infectious Disease Research Institute (IDRI), and a collaboration with Baylor College of Medicine to bring these technologies together to establish a vaccine consortium and develop multiple vaccine candidates, conduct comprehensive clinical testing, and to immediately further scale ImmunityBio’s manufacturing capabilities for global capacity for each of these vaccine candidates. The creation of this novel “mix-and-match” platform, which is also rapidly amenable to incorporation of variant constructs as they emerge, is aimed at establishing widespread availability of cost-effective...